What do you see as the biggest threat to the CDMO industry in 2026 or beyond?

Evolving investment trends continue to shape the biopharmaceutical landscape.
In the latest Pharma’s Almanac commentary, Associate Director of Market Intelligence Minjeong Seong offers perspective on how these shifts may influence project pipelines and CDMO priorities in the years ahead.

Evolving investment trends continue to shape the biopharmaceutical landscape.
In the latest Pharma’s Almanac commentary, Associate Director of Market Intelligence Minjeong Seong offers perspective on how these shifts may influence project pipelines and CDMO priorities in the years ahead.
Share article
Related Content